07/06/2018

# 論文代寫費用：18F的作用和問題

This Task conducted is an analytical and advisory report to the lab producing pharmaceuticals 18F, 99MO, 131I and 13N. The position assumed in this paper is that the isotope production and the overall demand, costs of waste management, compliance and more should dictate whether it should be discontinued in production or not. 18F goes by the name of Fludeoxyglucose (18F) (INN), or fludeoxyglucose F 18 (USAN and USP). It is a radio pharmaceutical as presented in the above fact sheet and is mainly used in the case of PET. The use of 18F and how it could contribute to issues for the person using it, is seen to be researched from the exposure perspective. It is PET/CT examinations that are used combined rather than that of the standalone PET and CT, because the effective dose is created only as such. Cancer risk induced for such form of radiation can be considered from multiple imaging perspectives, such as that of coronary CTs, mammography, and more.

Now research studies show that there is an associated cancer risk (Huang et al., 2009).Whole body PET/CT scanning is usually accompanied by radiation dose and cancer risk as well. In fact, the risk-benefit rations are seen to be high and clinical utility statistics and the study shows that it is necessary to use PET/CT scans by understanding the form of impact it could have on the person (Huang et al., 2009). This is especially important in such patients who have to undergo multiple treatments. In such patients where it is necessary to undergo multiple PET/CTs, as a result of which the exposure increases, the form of ‘response assessments’ should also have to increase. Although from a public viewpoint, it is stated that low doses being used presents non-negligible radiation, it is true that the use of 18F in PET/CT has to be carefully monitored and more studies have to be done to study risks (Huang et al., 2009).